Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a note issued to investors on Tuesday, June 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($1.29) per share for the year, down from their previous forecast of ($1.25). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($0.85) per share.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The firm had revenue of $12.54 million during the quarter, compared to analyst estimates of $25.67 million. During the same period in the previous year, the firm posted ($0.27) earnings per share.
Get Our Latest Stock Analysis on Wave Life Sciences
Wave Life Sciences Stock Performance
Shares of WVE opened at $4.99 on Friday. Wave Life Sciences has a 1 year low of $3.50 and a 1 year high of $7.67. The stock has a 50 day simple moving average of $5.72 and a 200-day simple moving average of $5.31. The stock has a market cap of $611.13 million, a PE ratio of -9.60 and a beta of -1.03.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Artal Group S.A. raised its stake in Wave Life Sciences by 34.7% during the 1st quarter. Artal Group S.A. now owns 4,051,400 shares of the company’s stock worth $24,997,000 after buying an additional 1,044,000 shares during the period. Ikarian Capital LLC acquired a new stake in Wave Life Sciences during the 1st quarter worth $3,641,000. Jacobs Levy Equity Management Inc. raised its stake in Wave Life Sciences by 13.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 241,860 shares of the company’s stock worth $1,492,000 after buying an additional 29,483 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Wave Life Sciences by 14.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,861,254 shares of the company’s stock worth $11,485,000 after buying an additional 233,891 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in Wave Life Sciences during the 1st quarter worth $1,768,000. 89.73% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Wave Life Sciences
In other news, CFO Kyle Moran sold 15,630 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total value of $96,437.10. Following the transaction, the chief financial officer now directly owns 33,921 shares in the company, valued at approximately $209,292.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 31.10% of the company’s stock.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Read More
- Five stocks we like better than Wave Life Sciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Using the MarketBeat Stock Split Calculator
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What are earnings reports?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.